anonymous
Guest
anonymous
Guest
Facts.
ESPR has to roll the dice to try to get additional funding.
Not encouraging.
Facts.
ESPR has to roll the dice to try to get additional funding.
Not encouraging.
KOLs are getting on board following the release of the parsed primary prevention data from CLEAR, which is definitely helping those in the field who promote the product. The end game is reducing events and the data don’t lie.
Oh, Karen!More gibberish from the Scientific Hires. KOL's are a worthless role and offer no help to field sales. This drug is toast ans has been for sometime
Having Nissen in our corner is a very good thing, the ripples turn into waves, then tsunamis. Outsiders can only look in and drool over their lost opportunities.
Having Nissen in our corner is a very good thing, the ripples turn into waves, then tsunamis. Outsiders can only look in and drool over their lost opportunities.
Oh, Karen.Ripples burn in to swirling the toilet bowl.
Now let's talk about the noise Currax is making for BA.
Nothing.
With stock at $1.39 I do not even know how Esperion is still paying the bills.
Later stage investors are typically the ones that are most richly rewarded, clearly you don’t know anything about finance. I’m not sure you know anything about anything long ESPR and look for a 10 bagger.
More excuses. Face facts and you don't have to be a Wall Street wizard to know that this is a dog stock. Look at how it's performed the last 3 years. Your post is comical at best.
Up 14% in a week extrapolates to a double in 5 weeks, 10 bagger before EOY. Simple math, easy money